Q06187 (BTK_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase BTK UniProtKBInterProSTRINGInteractive Modelling

659 aa; Sequence (Fasta) ; (Isoform 2; ) 11 identical sequences

Sequence Features

 521Proton acceptor.
 143Zinc.
 154Zinc.
 155Zinc.
 165Zinc.
 11L -> P (in XLA). VAR_006216
 12K -> R (in XLA). VAR_006217
 14S -> F (in XLA). VAR_006218
 19K -> E (in XLA). VAR_008291
 25F -> S (in XLA). VAR_006219
 27K -> R (in XLA). VAR_008292
 28R -> C (in XLA; no effect on phosphorylation of GTF2I). VAR_008293
 28R -> H (in XLA; moderate; dbSNP:rs128620185). VAR_006220 dbSNP
 28R -> P (in XLA). VAR_006221
 33T -> P (in XLA; severe; dbSNP:rs128620189). VAR_006222 dbSNP
 39Y -> S (in XLA). VAR_008960
 40Y -> C (in XLA; dbSNP:rs1555980875). VAR_008294 dbSNP
 40Y -> N (in XLA). VAR_008295
 61I -> N (in XLA). VAR_008296
 64V -> D (in XLA). VAR_008297
 64V -> F (in XLA). VAR_006223
 82R -> K (in dbSNP:rs56035945). VAR_041676 dbSNP
 103Q -> QSVFSSTR (in XLA). VAR_006224
 113V -> D (in XLA; dbSNP:rs128621190). VAR_006225 dbSNP
 115S -> F (in XLA). VAR_008298
 117T -> P (in XLA). VAR_008299
 127Q -> H (in XLA). VAR_008300
 154C -> S (in XLA). VAR_008301
 155C -> G (in XLA). VAR_008302
 155C -> R (in XLA). VAR_008303
 184T -> P (in XLA). VAR_008304
 190P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions). VAR_041677
 288R -> Q (in XLA; dbSNP:rs1555978277). VAR_008305 dbSNP
 288R -> W (in XLA; dbSNP:rs128621194). VAR_006227 dbSNP
 295L -> P (in XLA). VAR_006228
 302G -> E (in XLA). VAR_006230
 302G -> R (in XLA). VAR_008306
 302Missing (in XLA). VAR_006229
 307R -> G (in XLA; loss of activity; dbSNP:rs128621195). VAR_006231 dbSNP
 307R -> T (in XLA). VAR_008307
 308D -> E (in XLA). VAR_008308
 319V -> A (in XLA; moderate). VAR_008309
 334Y -> S (in XLA; dbSNP:rs128621196). VAR_006232 dbSNP
 358L -> F (in XLA). VAR_006233
 361Y -> C (in XLA; mild; dbSNP:rs28935478). VAR_006234 dbSNP
 362H -> Q (in XLA). VAR_006235
 364H -> P (in XLA). VAR_006236
 365N -> Y (in XLA). VAR_006237
 366S -> F (in XLA). VAR_008310
 369L -> F (in XLA). VAR_008311
 370I -> M (in XLA). VAR_006238
 372R -> G (in XLA). VAR_008312
 408L -> P (in XLA; moderate; dbSNP:rs128621198). VAR_006239 dbSNP
 414G -> R (in XLA). VAR_008313
 418Y -> H (in XLA; dbSNP:rs144079566). VAR_006240 dbSNP
 429I -> N (in XLA). VAR_006241
 430K -> E (in XLA; loss of phosphorylation of GTF2I; dbSNP:rs128620184). VAR_006242 dbSNP
 430K -> R (in XLA). VAR_008314
 445E -> D (in XLA). VAR_008315
 462G -> D (in XLA). VAR_008316
 462G -> V (in XLA). VAR_008317
 476Y -> D (in XLA). VAR_006243
 477M -> R (in XLA). VAR_006244
 481C -> S (found in patients with chronic lymphocytic leukemia; unknown pathological significance; results in resistance to ibrutinib therapy; results in a protein that is reversibly inhibited by ibrutinib; disrupts the covalent binding between the enzyme and ibrutinib; dbSNP:rs1057519825 and dbSNP:rs1057519826). VAR_074309 dbSNP
 502C -> F (in XLA). VAR_006245
 502C -> W (in XLA; dbSNP:rs41310709). VAR_006246 dbSNP
 506C -> R (in XLA; dbSNP:rs128621200). VAR_006247 dbSNP
 506C -> Y (in XLA). VAR_006248
 508A -> D (in XLA). VAR_008318
 509M -> I (in XLA). VAR_008319
 509M -> V (in XLA). VAR_006249
 512L -> P (in XLA). VAR_008961
 512L -> Q (in XLA). VAR_008962
 518L -> R (in XLA). VAR_008320
 520R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue; dbSNP:rs128621202). VAR_006251 dbSNP
 521D -> G (in XLA). VAR_008321
 521D -> H (in XLA; severe). VAR_006252
 521D -> N (in XLA; severe). VAR_006253
 523A -> E (in XLA). VAR_008322
 525R -> G (in XLA). VAR_008323
 525R -> P (in XLA). VAR_006254
 525R -> Q (in XLA; severe; disturbs ATP- binding; dbSNP:rs128620183). VAR_006255 dbSNP
 526N -> K (in XLA). VAR_006256
 535V -> F (in XLA). VAR_008324
 542L -> P (in XLA; growth hormone deficiency; dbSNP:rs128621203). VAR_006257 dbSNP
 544R -> G (in XLA). VAR_008963
 544R -> K (in XLA). VAR_006258
 559F -> S (in XLA). VAR_008325
 562R -> P (in XLA; dbSNP:rs104894770). VAR_006259 dbSNP
 562R -> W (in XLA; dbSNP:rs128621204). VAR_006260 dbSNP
 563W -> L (in XLA; dbSNP:rs1555977474). VAR_008326 dbSNP
 567E -> K (in XLA; severe). VAR_006261
 578S -> Y (in XLA). VAR_008964
 581W -> R (in XLA; dbSNP:rs128621205). VAR_006262 dbSNP
 582A -> V (in XLA). VAR_006263
 583F -> S (in XLA). VAR_008327
 587M -> L (in XLA; mild). VAR_006264
 589E -> D (in XLA). VAR_008328
 589E -> G (in XLA; moderate; interferes with substrate binding; dbSNP:rs128621206). VAR_006265 dbSNP
 589E -> K (in XLA). VAR_008965
 592S -> P (in XLA). VAR_006267
 594G -> E (in XLA; mild; interferes with substrate binding). VAR_006268
 594G -> R (in XLA; dbSNP:rs1555977339). VAR_006269 dbSNP
 598Y -> C (in XLA). VAR_006270
 607A -> D (in XLA; mild; dbSNP:rs128621208). VAR_006271 dbSNP
 613G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions; dbSNP:rs128621209). VAR_006272 dbSNP
 619P -> A (in XLA). VAR_008330
 619P -> S (in XLA). VAR_006273
 619P -> T (in XLA). VAR_008331
 622A -> P (in XLA). VAR_008332
 626V -> G (in XLA). VAR_008333
 630M -> I (polymorphism, 35%). VAR_006274
 630M -> K (in XLA; dbSNP:rs128621210). VAR_006275 dbSNP
 630M -> T (in XLA). VAR_008334
 633C -> Y (in XLA). VAR_006276
 641R -> C (in XLA). VAR_006277
 641R -> H (in XLA; severe). VAR_006278
 644F -> L (in XLA). VAR_008335
 644F -> S (in XLA). VAR_006279
 647L -> P (in XLA). VAR_006280
 652L -> P (in XLA; dbSNP:rs128622212). VAR_006281 dbSNP
 135-171Btk-type.
 408-416ATP.
 260-280Missing (in XLA; severe). VAR_006226
 5-133Pleckstrin homology domain
IPR001849PF00169
 141-167Zinc finger, Btk motif
IPR001562PF00779
 220-266SH3 domain
IPR001452PF00018
 281-362SH2 domain
IPR000980PF00017
 402-650Serine-threonine/tyrosine-protein kinase, catalytic domain
IPR001245PF07714

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRangeDownloadAssess
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dih... Heteromer
4×N42;5j87385-658
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4homo-4-mer 4×ZN; 8×4IP;1bwn2-170
PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATEhomo-4-mer 4×ZN; 4×4IP;1b552-170
Crystal structure of the human BTK kinase domainhomo-2-mer 3p08394-658
The structure of human BTK kinase domain in complex with a covalent inhibitorhomo-2-mer 2×GYL;5xyz394-656
CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OX...homo-2-mer 2×6MV;5jrs396-656
Crystal structure of Bruton's tyrosine kinase domainhomo-2-mer 1k2p397-654
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28Chomo-2-mer 2×NA; 2×ZN;1btk2-170
Crystal structure of PH domain of Bruton's tyrosine kinasehomo-2-mer 2×ZN; 2×4PT;2z0p2-170
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGANDmonomer 1×GJD;6di1389-659
BTK1 SOAKED WITH IBRUTINIB-Revmonomer 1×1E8; 2×DMS;5p9i389-659
CRYSTAL STRUCTURE OF BTK with CNX 774monomer 1×7G8;5p9k389-659
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer 1×GJG;6di0389-659
'Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a D...monomer 1×83P; 2×PEG; 3×EDO;5u9d389-659
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydro...monomer 1×KLM; 6×EDO;6nfh389-659
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinibmonomer 1×MZJ; 1×CL;6omu389-659
BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059monomer 1×DMS; 1×7GB;5p9m389-659
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer 1×GJ7; 1×DMS;6di5389-659
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(...monomer 1×4US; 1×DMS; 2×EDO;5bq0389-659
Bruton's tyrosine kinase (BTK) with GDC-0853monomer 2×SO4; 8×EDO; 1×9AJ;5vfi389-659
Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinasemonomer 1×IPA; 2×IMD; 1×4L6; 1×EDO;4z3v389-659
Discovery of affinity-based probes for Btk occupancy assaymonomer 1×KHD;6n9p389-659
Crystal structure of ARQ 531 in complex with the kinase domain of BTKmonomer 1×HRA; 2×IMD; 2×EDO;6e4f389-658
Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragmentmonomer 1×4RU; 1×IPA; 1×DMS; 2×IMD;4zly389-658
Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnolinemonomer 1×IPA; 1×DMS; 2×IMD; 1×4RV;4zlz389-658
Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6...monomer 1×04K;3pj2391-659
Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N...monomer 1×04L;3pj3391-659
Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamin...monomer 2×LHL;3pj1391-659
Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-m...monomer 1×03C;3piz391-659
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer 1×DMS; 1×GJJ;6di9392-659
BTK In Complex With Inhibitormonomer 1×LTJ;6o8i391-658
Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(...monomer 1×027;3pix391-658
BTK-inhibitor co-structuremonomer 1×5WH; 1×5WE;5fbo392-659
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitormonomer 9×NA; 2×SO4; 3×CL; 2×EDO; 1×4C9;4yhf391-658
'BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyr...monomer 1×KLP; 2×SO4;6nfi392-659
Crystal structure of BTK kinase domain complexed with R406monomer 1×585;3piy391-658
Co-crystal structure of BTK kinase domain with Zanubrutinibmonomer 1×IMD; 1×BA0;6j6m393-659
The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-contai...monomer 1×B43;3gen392-658
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mech...monomer 1×1N1;3k54392-658
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer 1×GJA;6di3393-659
BTK1 COCRYSTALLIZED WITH IBRUTINIBmonomer 1×8E8;5p9j394-659
BTK1 IN COMPLEX WITH CC 292monomer 1×7G9;5p9l392-657
BTK IN COMPLEX WITH GDC-0834monomer 1×GOL; 4×EDO; 1×2VL;5p9f394-659
BTK complex with compound 12monomer 2×GOL; 1×DXM; 3×SO4; 1×FPZ;6bkw393-657
Brutons tyrosine kinase in complex with compound 50.monomer 1×EDO; 1×L9S;6nzm395-659
Structure of BTK with RN486monomer 1×7G6;5p9g394-658
Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-...monomer 1×2V1;4ot6394-658
Bruton's tyrosine kinase (BTK) with pyridazinone compound 23monomer 2×GOL; 1×3YO; 2×SO4; 1×PG0;4rx5394-657
Bruton's tyrosine kinase (BTK) with pyridazinone compound 9monomer 2×GOL; 2×SO4; 1×PG0; 1×6XL;5kup394-657
Bruton's tyrosine kinase (BTK) with compound G-744monomer 2×GOL; 2×SO4; 2×PG0; 1×9B1;5vgo394-657
BTK kinase domain with inhibitor 1monomer 1×5WF; 1×5WE; 1×CL;5fbn395-658
BTK1 COCRYSTALLIZED WITH RN983monomer 1×7G7;5p9h395-658
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1...monomer 1×GMQ;6hrp396-658
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymet...monomer 2×DMS; 1×3OV;4rfz396-658
BTK complex with compound 13monomer 1×DY4; 1×GOL; 3×SO4;6bln395-657
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-...monomer 1×GMW;6hrt396-658
Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-...monomer 1×73T;5t18396-658
Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl...monomer 1×2V2; 2×DMS;4otq396-658
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazin...monomer 2×DMS; 1×481;4ot5396-658
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815monomer 1×BXM; 2×SO4;6aub395-657
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625monomer 1×GOL; 1×BXJ; 2×SO4;6aua394-656
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1...monomer 2×DMS; 1×3OU;4rfy396-658
BTK complex with compound 7monomer 1×DTJ; 3×SO4; 1×GOL;6bik395-657
Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin...monomer 1×2V3; 2×DMS;4otr396-658
Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinibmonomer 1×1N1;3oct394-656
BTK complex with compound 10monomer 3×SO4; 1×DVJ;6bke395-657
Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiper...monomer 1×BNB;6ep9396-658
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methy...monomer 1×3P0;4rg0396-658
BTK complex with compound 11monomer 1×DVD; 4×SO4;6bkh396-657
Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746monomer 3×SO4; 1×746; 1×BME;3ocs395-656
BTK in complex with an inhibitormonomer 1×L0Z;6s90395-656
Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834monomer 3×SO4; 1×2VL;4otf396-657
Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-te...monomer 1×2P5;4nwm396-657
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(...monomer 1×4UQ;5bpy396-657
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2emonomer 1×9M3;5zz4395-655
Solution Structures of the SH2 domain of Bruton's Tyrosine Kinasemonomer 2ge9270-387
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURESmonomer 1aww211-275
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTUREmonomer 1awx211-275
NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structuresmonomer 1qly216-273

Homology models

Oligo-stateLigandsQMEANTemplateRangeSeq id (%)ReportDownloadAssess
monomer 1×AU;-1.424xi2.1.A214-657
98.21
monomer -1.921opl.2.A275-657
39.68
monomer -2.781y57.1.A217-657
38.62
monomer -2.682fo0.1.A216-658
39.77

Homology models built on isoform sequence

Isoform #Oligo-stateLigandsQMEANTemplateRangeSeq id (%)ReportDownloadAssess
2monomer1×AU;-1.424xi2.1.A248-691
98.21
2monomer-1.921opl.2.A309-691
39.68
2monomer-2.781y57.1.A251-691
38.62
2monomer-2.742fo0.1.A250-692
40.00